Short hairpin RNA-mediated matrix gene silencing of human respiratory syncytial virus as a potent antiviral strategy

IF 2.1 4区 医学 Q3 VIROLOGY
Saeid Amiri Zadeh Fard, Haniyeh Abuei, A. Farhadi, Gholamreza Rafiei Dehbidi, F. Zare, Zahra Abbasfard, A. Behbahani
{"title":"Short hairpin RNA-mediated matrix gene silencing of human respiratory syncytial virus as a potent antiviral strategy","authors":"Saeid Amiri Zadeh Fard, Haniyeh Abuei, A. Farhadi, Gholamreza Rafiei Dehbidi, F. Zare, Zahra Abbasfard, A. Behbahani","doi":"10.2217/fvl-2022-0207","DOIUrl":null,"url":null,"abstract":"Aim: Human respiratory syncytial virus (HRSV) is a common cause of respiratory infections, particularly in infants and the elderly. Ribavirin is the only US FDA-approved antiviral drug for HRSV infection, but it has unwanted side effects. Methods: We engineered an shRNA targeting the HRSV- M gene to antagonize HRSV replication. Results: The results showed that shRNA had a similarly significant reduction in viral load (99.8%) as ribavirin. In addition, combined treatment with ribavirin and M-shRNA resulted in a significant reduction in viral load compared with ribavirin or M-shRNA alone. Conclusion: These results suggest that M-shRNA could be a potential new inhibitor of HRSV replication and could offer a safer and more effective treatment option for HRSV infection in the future.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2023-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Virology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/fvl-2022-0207","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: Human respiratory syncytial virus (HRSV) is a common cause of respiratory infections, particularly in infants and the elderly. Ribavirin is the only US FDA-approved antiviral drug for HRSV infection, but it has unwanted side effects. Methods: We engineered an shRNA targeting the HRSV- M gene to antagonize HRSV replication. Results: The results showed that shRNA had a similarly significant reduction in viral load (99.8%) as ribavirin. In addition, combined treatment with ribavirin and M-shRNA resulted in a significant reduction in viral load compared with ribavirin or M-shRNA alone. Conclusion: These results suggest that M-shRNA could be a potential new inhibitor of HRSV replication and could offer a safer and more effective treatment option for HRSV infection in the future.
短发夹RNA介导的人呼吸道合胞病毒基质基因沉默作为一种有效的抗病毒策略
目的:人呼吸道合胞病毒(HRSV)是呼吸道感染的常见原因,特别是在婴儿和老年人中。利巴韦林是美国fda批准的唯一一种治疗HRSV感染的抗病毒药物,但是它有副作用。方法:我们设计了一种靶向HRSV- M基因的shRNA来对抗HRSV的复制。结果:结果表明shRNA与利巴韦林具有相似的显著的病毒载量降低(99.8%)。此外,与单独使用利巴韦林或M-shRNA相比,利巴韦林和M-shRNA联合治疗可显著降低病毒载量。结论:这些结果提示M-shRNA可能是一种潜在的新的HRSV复制抑制剂,并可能在未来为HRSV感染提供更安全、更有效的治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Future Virology
Future Virology 医学-病毒学
CiteScore
4.00
自引率
3.20%
发文量
84
审稿时长
6-12 weeks
期刊介绍: Future Virology is a peer-reviewed journal that delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this ever-expanding area of research. It is an interdisciplinary forum for all scientists working in the field today.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信